ABSTRACT: In this review, we provide a framework for clinical decision-making in the treatment of differentiated thyroid cancer. The clinical discussion and treatment recommendations are relevant to an adult population (more than 16 years of age). The natural history, pathogenesis, diagnostic tools, and treatment controversies in the management of this disease are explored. The roles of radioiodine therapy and thyroid-stimulating hormone (TSH) suppression and the treatment of locoregional disease are reviewed. This discussion provides a comprehensive assessment of management and treatment issues in differentiated thyroid cancer. [ONCOLOGY 12(1):99-106, 1998]
Thyroid cancer has attracted interest because of its broad range of biologic phenotypes, ranging from the treatable papillary carcinomas to the often lethal anaplastic thyroid carcinoma. The most common thyroid cancers are the differentiated thyroid carcinomas, which, in general, carry high long-term survival rates.
Partly because of the low mortality and prolonged recurrence patterns of differentiated thyroid carcinomas, prospective randomized trials have not been conducted. Hence, despite the well-documented natural history of this cancer, its treatment remains controversial.
The emergence and widespread acceptance of risk group assignment in the management of differentiated thyroid cancer have diminished some of the clinical controversy surrounding its treatment. Recent progress in identifying the molecular events associated with the malignant transformation of the thyroid follicular cell has opened up the possibility that clinical treatment decisions can be based on the biologic mechanism of the disease process.
An estimated 15,600 thyroid malignancies will be treated in the United States this year. Of these, 80% to 90% will be well-differentiated thyroid cancers. Papillary carcinoma accounts for 70% of all differentiated thyroid cancer cases. The incidence of papillary cancer is increasing, with the peak age of occurrence between the third and fourth decades of life. Also, 90% of radiation-induced thyroid malignancies are diagnosed as papillary carcinomas. Despite its incidence, the overall mortality of papillary carcinoma remains low (6% to 12%).[2,3] Regional lymph node metastases occur in 30% to 60% of patients with papillary carcinoma. Nevertheless, when compared to other epithelial malignancies, the biologic behavior of papillary carcinoma is indolent, especially in adults less than 45 years of age. Long-term survival is common, even with persistent or recurrent disease (Table 1).
Follicular carcinomas are more commonly found in association with endemic goiter and geographic areas of chronic iodine deficiency. The peak incidence of follicular carcinoma is in the fifth to sixth decades of life. Histologically, follicular carcinomas have been classified as microinvasive (low-grade) or macroinvasive (high-grade) carcinomas. The distinctive histologic feature of high-grade lesions is angioinvasion. Microinvasive follicular carcinomas have a less aggressive clinical course with low rates of metastasis. Conversely, macroinvasive follicular carcinomas carry a poorer prognosis with higher rates of metastases. The more aggressive follicular thyroid carcinomas tend to occur in men over 50 years of age.
Although the pathogenesis of differentiated thyroid cancer is unknown, some theories suggest an association with such clinical syndromes as adenomatous polyposis. The existence of a number of defective signal transduction factors (ras, ret, gsp, trk), as well as nuclear regulatory factors (eg, p53, retinoblastoma gene), has been implicated in the pathogenesis of differentiated thyroid carcinoma, implying potential familial inheritance patterns (Figure 1).[9,10]
One of the more clearly defined genetic events in differentiated thyroid cancer is the involvement of the RET proto-oncogene in papillary carcinoma (Figure 2).[11,12] Through a pericentromeric inversion in chromosome 10, the position of the RET proto-oncogene is rearranged. After the inversion, the gene is repositioned in front of a promoter, thereby activating it. The rearranged gene, called the papillary thyroid carcinoma oncogene (PTC), is seen in up to 40% of papillary cancers.
Most patients with differentiated thyroid cancer present with a solitary, asymptomatic, hypofunctional nodule within the thyroid. Thirty percent of lesions are smaller than 1.5 cm.[12-14] On occasion, the only positive clinical finding is palpable cervical adenopathy harboring metastatic disease.
From 6% to 10% of the adult US population have solitary thyroid nodules, and only 5% of these are malignant. Hence, the first diagnostic challenge is to identify this relatively small population with malignancy. The next challenge is to detect thyroid carcinomas that are likely to display an aggressive biologic phenotype.
Fine-needle aspiration (FNA) remains the best single diagnostic tool (Figure 3). It carries a negative predictive value of 94% for benign disease and a positive predictive value of 96% for malignant disease. If one takes into account those patients with indeterminate or inadequate FNA, the positive predictive value is still over 50%. In comparison, scintigraphy and ultrasound have a positive predictive value of only 20%.
A malignant FNA cytology mandates surgical resection with no further work-up. A cystic lesion that completely resolves after FNA warrants no other treatment. Surgical intervention is recommended only if the mass persists or reappears following aspiration. Benign pathology on FNA can be followed by periodic clinical and ultrasound examination, as well as by thyroid-stimulating hormone (TSH) suppression.
Inadequate FNA cytology often results from technical error and should be repeated. Indeterminate FNA is usually secondary to the cytologist’s inability to differentiate follicular adenoma from follicular carcinoma (false-negative rate, 27%). Under these circumstances, two clinical paradigms can be used.
In patients in whom the TSH level is normal or elevated, the clinician can reasonably assume that the nodule is hypofunctioning. This implies an increased probability of malignancy, and thus, surgical resection can be recommended without further diagnostic work-up. An equally accepted clinical strategy is to perform scintigraphy in these patients. Patients with a hypofunctioning nodule would be triaged to surgery. Those with a hyperfunctioning nodule receive a trial of suppression therapy. Interestingly, malignant foci occur in 80% of lesions larger than 4 cm. Therefore, in patients with large lesions, immediate surgical intervention can be considered without additional diagnostic testing.
Response to TSH suppression is not a reliable predictor of malignant potential in a solitary thyroid nodule. Fifteen percent of patients placed on TSH suppression and followed by serial ultrasounds showed continued lesion growth, 20% demonstrated regression, and 65% showed no change. In the case of total resolution with TSH suppression, further treatment, aside from periodic surveillance, is unnecessary.
Thyroid ultrasound is helpful in detecting small nodules or ruling out contralateral disease. Occult nodules less than 1 cm in size detected incidentally on imaging studies (ultrasound, CT) can simply be followed by serial examinations in most cases. To assuage clinical concern about the benign nature of these lesions, an image-guided FNA should be appropriate.
Over the past decade, prognostic factors for differentiated thyroid cancer were identified using multivariate analysis from large retrospective series. The major prognostic variables can be divided into patient- and tumor-related risk factors. Age is the only patient-related risk factor that significantly affects survival (Table 2). The tumor-related risk factors are size, presence or absence of extrathyroidal extension, and distant metastasis.
A number of patient-risk assignment systems were developed using these prognostic factors (Table 3). The four systems we will discuss are the AMES (Lahey Clinic), AGES-MACIS (Mayo Clinic),[19,20] University of Chicago, and Memorial Sloan-Kettering systems.[21,22] These systems use patient- and tumor-related risk factors (age, distant metastasis, extrathyroidal extension, and tumor size) as prognostic variables. The only exception is the University of Chicago system, which uses all of these variables except tumor size (Table 3). The differences between the various systems are based on the weighted influence these prognostic factors have on the risk of a patient developing local, regional, or distant metastases.
The AMES system assigns patients to the low-risk group if they are men less than 40 years old or women younger than 50 and are free of distant metastasis. Given these criteria of age or gender, patients are further assigned to the low-risk group if their tumor is less than 5 cm, has no extrathyroidal extension, and has a favorable histology (microinvasive follicular car- cinoma). All other patients who do not meet the above criteria are considered to be at high risk.
The AGES (Mayo) system determines risk group assignment by using a weighted scoring system based on the aforementioned prognostic factors. The MACIS system is a modification of the AGES system in which tumor grade has been replaced by distant metastases and margin status.
The Memorial Sloan-Kettering staging system assigns patients to low-, intermediate-, and high-risk groups. Low-risk patients are those who are less than 45 years old and have favorable tumor-related factors (Table 3). Patients in the high-risk group are age 45 or older with adverse tumor-related risk factors. Those assigned to the intermediate-risk group are under age 45 with adverse tumor-related factors or older than 45 with favorable tumor-related factors.
The impact of the more aggressive histologic subtypes, such as tall cell variant of papillary carcinoma, is not well understood. Most studies do not define histologic subtypes sufficiently to assign a significant predictive value to histologic grade. However, poor differentiation and tall cell variants of papillary carcinoma should be considered unfavorable subtypes.
Multifocality and Cervical Node Metastasis
Despite the high incidence of multifocality in papillary thyroid cancer, the recurrence rate in unresected thyroid tissue is less then 10%.[25,26] Several studies corroborate the finding that multifocality does not carry prognostic significance.[21,27-29]
Similarly, up to 40% of patients with differentiated thyroid carcinoma have microscopic, occult cervical lymph node metastases. The impact on survival of occult or clinically evident cervical metastases is unclear. However, most studies agree that N1 disease does not affect overall survival.[27-29,31] The Lahey group and others[21,32,33] reported that, after univariate analysis, cervical lymph node metastases are a favorable indicator of survival. This particular outcome analysis failed to adjust for patient age, however.
In both the Sloan-Kettering and Lahey series, the favorable impact of nodal metastases on survival disappeared with multivariate analysis.[21,24] In a matched pair study at Sloan-Kettering, all N1 patients had more recurrences and yet similar survival when compared to N0 patients. However, for patients over 45 years of age with nodal metastases, survival was negatively affected. This finding was supported by two other retrospective studies.[36,37]
1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996.
2. Jensen MH, Davis K, Derrick L: Thyroid cancer: A computer-assisted review of 5287 cases. Otolaryngol Head Neck Surg 102:51-65, 1990.
3. Nikiforov Y, Gnepp DR, Fajin JM: Thyroid lesions in children and adolescent after the Chernobyl disaster: Implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab 81:9-14, 1996.
4. Cuello C, Correa P, Eisenberg H: Geographic pathology of thyroid carcinoma. Cancer 23:230-239, 1969.
5. Thompson NW: Endocrine neoplasia, in Niederhuber JE (ed): Current Therapy in Oncology, pp 240-248. St. Louis, Mosby Year Book-B.C. Decker, 1993
6. Shaha AR, Loree TL, Shah JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131-1138, 1995.
7. Lang W, Choritz H, Hundeshagen H: Risk factors in follicular thyroid carcinomas: A retrospective follow-up study covering a 14 year period with emphasis on morphological findings. Am J Surg Pathol 10:246-255, 1986.
8. DeGroot LJ, Kaplan EL, McCormick M, et al: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424, 1990.
9. Farid NR, Shi Y, Minjing Z: Molecular basis of thyroid cancer. Endocrine Rev 15:202-232, 1994.
10. Taruscio D, Carcangui ML, Ried T, et al: Numerical chromosome alterations in thyroid tumors detected by double fluorescence in situ hybridization. Genes Chromosomes Cancer 9:180-185, 1994.
11. Grieco M, Santoro M, Berlingieri MT, et al: PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinoma. Cell 60:557-563, 1990.
12. Bongarzone I, Butti MG, Coronelli S, et al: Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54:2979-2985, 1994.
13. Hay ID, Grant CS, van Heerden JA, et al: Papillary thyroid microcarcinoma: A study of 535 cases observed in a 50-year period. Surgery 112:1139-1147, 1992.
14. Lin JD, Chao TC, Weng HF, et al: Clinical presentation and treatment of 74 occult thyroid carcinomas. Am J Clin Oncol 19:504-508, 1996.
15. Woeber KA: Cost-Effective evaluation of the patient with a thyroid nodule. Surg Clin North Am 75:357-363, 1995.
16. Saunders LE, Rossi RL: Occult well differentiated carcinoma presenting as cervical node disease. World J Surg 19:642-647, 1995
17. Reverter RL, Lucas A, Salinas I, et al: Suppressive therapy with levothyroxine for solitary nodules. Clin Endocrinol 36:25-29, 1992.
18. Cady B, Rossi R: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947-953, 1988.
19. Hay ID, Grant CS, Taylor WF, et al: Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088- 1095, 1987.
20. Hay ID, Bergstrath EJ, Goellner JR, et al: Predicting outcome in papillary carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058, 1993.
21. Shah, JP, Loree TL, Dharker D, et al: Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surgery 164:658-661, 1992.
22. Shaha AR, Loree TL, Shah JP: Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery 116:1036-1041, 1994.
23. Shaha AR, Loree TL, Shah JP: Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118:1131-1138, 1995.
24. Terry JH, St. John SA, Karkowski FJ et al: Tall cell papillary thyroid cancer: Incidence and prognosis. Am J Surg 168:459-461, 1994.
25. Russel MA, Gilbert EF, Jaeschke WR: Prognostic features of thyroid cancer. Cancer 36:553-559, 1975.
26. Tollefsen HR, Shah JP, Huvos AG: Papillary carcinoma of the thyroid: Recurrence in the thyroid gland after initial surgical treatment. Am J Surg 124:468-472, 1972.
27. McConahey WM, Hay ID, Woolner LB, et al: Papillary thyroid cancer treated at the Mayo Clinic 1946 through 1970: Initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc 61:968-975, 1986.
28. Rossi RL, Cady B, Silverman ML, et al: Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg 10:612- 622, 1986.
29. Coburn MC, Wanebo HJ: Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 164:671-676, 1992.
30. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576, 1994.
31. Cunningham MP, Duda RB, Recant W, et al: Survival discriminants for differentiated thyroid cancer. Am J Surg 160:344-347, 1990.
32. Hirabayashi RN, Lindsay S: Carcinoma of the thyroid gland: A statistical study of 390 patients. J Clin Endocrinol Metab 21:1596-1610, 1961.
33. Cady B, Sedwick CE, Meissner WA, et al: Changing clinical, pathological, therapeutic, and survival patterns in differentiated thyroid cancer. Ann Surg 18:541-553, 1976.
34. Rossi RL, Nieroda C, Cady B, Wool MS: Malignancies of the thyroid gland: The Lahey Clinic experience. Surg Clin North Am 65:211-230, 1985.
35. Hughes CJ, Shaha AR, Shah JP, et al: Impact of lymph node metastases in differentiated carcinoma of the thyroid: a matched pair analysis. Head & Neck 18:127-132, 1996.
36. Harwood J, Clark OH, Dunphy JE: Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg 136:107-112, 1978.
37. Sellers M, Beenken S, Blankenship A: Prognostic significance of cervical lymph node metastasis in differentiated thyroid cancer. Am J Surg 164:578-581, 1992.
38. Mazzaferri E, Young RL: Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518, 1981.
39. Shah JP, Loree TR, Dharker D, et al: Lobectomy versus total thyroidectomy for differentiated carcinoma of the thyroid: A matched pair analysis. Am J Surg 166:331-335, 1993.
40. Clark OH, Levin K, Zeng Q, et al: Thyroid cancer: The case for total thyroidectomy. Eur J Clin Oncol 24:305-313, 1988.
41. Beierwaltes WH, Rabbani R, Dmuchowski C, et al: An analysis of “ablation of thyroid remnants” with I131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 25:1287-1293, 1984.
42. Varma VM, Beierwaltes WH, Nofal MM, et al: Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA 214:1437-1442, 1970.
43. Hay ID, Grebe SK: Relative value of medical treatment with radioactive iodine and thyroid suppression as adjuvants after primary surgery for differentiated follicular-cell derived thyroid carcinoma. Proc 4th Int Conf Head Neck Cancer, pp 988-994, 1996.
44. Cohn KH, Backdahl M, Forsslund G, et al: Biologic considerations and operative strategy in papillary thyroid carcinoma: Arguments against the routine performance of total thyroidectomy. Surgery 96:957-970, 1984.
45. Schroder DM, Chambers A, France CJ: Operative strategy for thyroid cancer: Is total thyroidectomy worth the price? Cancer 58:2320-2328, 1986.
46. Loree TR: Therapeutic implications of prognostic factors in differentiated carcinoma of the thyroid gland. Semin Surg Oncol 11:246-255,1995.
47. Harness JK, Fung L, Thompson MN, et al: Total thyroidectomy: Complications and technique. World J Surg 10:781-786, 1986.
48. Flynn MB, Lyons KJ, Tarter JW, et al: Local complications after surgical resection for thyroid carcinoma. Am J Surg 168:404-407, 1994.
49. Van Heerden JA, Groh MA, Grant GS: Early postoperative morbidity after surgical treatment of thyroid carcinoma. Surgery 101:224-227, 1987.
50. Goepfert H, Callender DL: Differentiated thyroid cancer: Papillary and follicular carcinomas. Am J Otol 15:164-179, 1994.
51. Scheumann GFW, Grimm O, Wegener G, et al: Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559-568, 1994.
52. McGregor GI, Luoma A, Jackson SM: Lymph node metastases from well differentiated thyroid cancer: A clinical review. Am J Surg 149:610-612, 1985.
53. Mazzaferri EL: Papillary thyroid carcinoma: Factors influencing prognosis and current therapy. Semin Oncol 14:315-332, 1987.
54. Joensuu H, Klemi PJ, Paul R, et al: Survival and prognostic factors in thyroid carcinoma. Acta Radiol Oncol 25:243-248, 1986.
55. Maxon HR, Smith HS: Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 19:685-718, 1990.
56. Samaan NA, Schultz PN, Hickey RC, et al: The results of various modalities of treatment of well-differentiated thyroid carcinomas: A retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720, 1992.
57. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 95:418-428, 1994.
58. DeGroot LJ, Kaplan EL, Shukla MS, et al: Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80:2946-2953, 1995.
59. Hay ID: Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576, 1990.
60. Young RL, Mazzaferri EL, Rahe SM, et al: Pure follicular thyroid carcinoma: Impact of therapy in 214 patients. J Nucl Med 21:733-738, 1980.
61. Tubiana M, Schlumberger M, Rougier P, et al: Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794-804, 1985.
62. Snyder J, Gorman C, Scanlon P: Thyroid remnant ablation: Questionable pursuit of an ill-defined goal. J Nucl Med 24:659-665, 1983.
63. Edmonds CJ, Smith T: The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45-51, 1986.
64. Szanto J, Ringwald G, Karika Z, et al: Follicular cancer of the thyroid gland. Oncology 48:483-489, 1991.
65. Ruegemer J, Hay ID, Bergstrahl EJ, et al: Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508, 1988.
66. Mazzaferri EL, Young RL, Oertel JE, et al: Papillary thyroid carcinomas: The impact of therapy in 576 patients. Medicine 56:171-196, 1977.
67. Roti E, Minelli R, Gardini E, et al: The use and misuse of thyroid hormone. Endocrinol Rev 14:401-418, 1993.
68. Kobayashi T, Asakawa H, Yasuhiro T, et al: Fatal differentiated thyroid cancer. J Surg Oncol 62:123-127, 1996.
69. Brown AP, Greening WP, McCready VR, et al: Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. Br J Radiol 57:323-327, 1984.
70. Har-El G: Locally aggressive differentiated thyroid cancer. Proc 4th Int Conf Head Neck, pp 972-987, 1996.
71. Powell S, Harmer C: Thyroid cancer causing death after 40 years: Rationale for initial intensive treatment. Eur J Surg Oncol 16:457-461, 1990.
72. Ross DS: Long-term management of differentiated thyroid cancer. Endocrinol Clin North Am 19:719-739, 1990.
73. Ozaka M, Suzuki S, Miyamoto T, Lui TR, et al: Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98-105, 1994.
74. Van de Velde CJH, Hamming JF, Goslings BM, et al: Report of the consensus development conference on the management of differentiated thyroid cancer in the Nederlands. Eur J Cancer Clin Oncol 24:287-292, 1988.